TP53 and Hyperglycemia: By actively participating in PARP-1/p53 DNA repair signalling cascades, our formulated novel NPIP inhibited overall nuclear damage and genotoxicity triggered by diabetes/hyperglycemia, in both in vitro and in vivo model which might be dedicated to their greater tissue/ cellular internalization, penetration, and availability owing to their nano-size range when compared to unencapsulated/ naked PIP.